Cite
HARVARD Citation
Nelander, K. et al. (2021). Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction. Clinical and translational science. 14 (3), pp. 812-819. [Online].